
Krishna Institute of Medical Sciences Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- KIMS expects a steady revenue growth of around 10% year-on-year for mature hospitals and clusters like Telangana and Andhra Pradesh (AP), driven by volume growth, price hikes, and case mix improvements.
- Volume growth in AP inpatient services is around 6%, with overall cluster growth aided by new specialties and bed additions.
- New bed capacity additions, e.g., 100 incremental beds in Kondapur Phase 1 by Q1 FY '26 and full 500-550 beds by Q1 FY '27, are expected to boost revenue.
- The ramp-up of new doctors, especially in Telangana and AP clusters, is expected to accelerate growth reaching around 15-20% in some quarters.
- Sunshine and Nagpur hospitals are showing encouraging growth with plans for revenue expansion and margin improvement.
- Pricing adjustments with insurance companies, including a potential 20-30% hike from GIPSA, will contribute to revenue growth.
- Overall, KIMS targets a consistent 10% revenue growth with occasional higher growth during capacity expansions.
See what Krishna Institute of Medical Sciences management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- No explicit mention of any immediate new fundraising through debt or equity in the transcript.
- Current capex for FY24 was around INR 650 crores, FY25 anticipated INR 400-600 crores, funded through existing debt and internal accruals.
- Debt levels have increased mainly due to acquisitions and ongoing projects like Thane, Bangalore, Nashik; total debt still being managed within a debt-equity target of 0.7 and debt-EBITDA of 1.5.
- Management emphasizes disciplined capital deployment with preference for asset-light O&M (operations and management) contracts with buyback options to limit capital infusion.
- Future debt repayment expected after FY26 as existing projects stabilize; no indication of additional fundraise planned before then.
- The company appears focused on controlling leverage rather than raising new equity or debt in the near term.
See what Krishna Institute of Medical Sciences management said on order book — free account, 30 seconds.
Capex plans
Yes- FY24 capex incurred was approximately INR 650 crore, including land and building at Thane.
- FY25 anticipated capex is between INR 400 crore and INR 600 crore.
- Key projects include Bangalore (2 hospitals: 450-bed Marathahalli and 300-bed South Bangalore), Thane, Nashik, and Kondapur expansions.
- Bangalore hospital (Marathahalli) cost ~INR 1 crore/bed; South Bangalore hospital is on a revenue-share model with INR 70-80 lakh/bed.
- Thane hospital total capex expected around INR 515 crore, with potential to add 150 beds in Phase 2 at lower cost.
- Kondapur expansion divided into two phases: incremental 100 beds commissioned early FY26 and full 500-550 beds by Q1 FY27.
- Strategy favors asset-light models and partnerships to limit capital commitment.
- Debt repayments expected to start post FY26 with target debt-to-equity of 0.7 and debt-to-EBITDA of 1.5.
Track Krishna Institute of Medical Sciences — get its next earnings analysis in your feed
How does Krishna Institute of Medical Sciences rank vs peers in Healthcare Services?
Pro featureHow does Krishna Institute of Medical Sciences rank in Healthcare Services?
Compare Krishna Institute of Medical Sciences against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Krishna Institute of Medical Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.